What Is the Treatment of Acute Angioedema Attacks in Hereditary C1 Inhibitor Deficiency?

Clinical Scenario

A patient with hereditary C1 inhibitor deficiency presenting with an acute angioedema attack requiring prompt first-line on-demand intervention at the earliest possible moment after symptom onset.

First-Line Approach

FDA-approved on-demand medications are available and can be self-administered — or administered by a caregiver — as early as possible at attack onset.

The complete medication options, selection criteria, and administration details are in the full structured protocol below.

Treatment Goal

Onset of relief from angioedema swelling within 30 to 120 minutes of treatment initiation.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jaip.2020.08.046

An FDA-approved on-demand HAE medication (ecallantide, icatibant, pdC1INH, or rhC1INH) should be used as first-line treatment for attacks whenever possible.
On-demand treatment of HAE attacks should be self-administered (or administered by a caregiver) whenever feasible except when treating with ecallantide that needs to be administered by a health care provider.
On-demand treatment of attacks is most effective when administered early after attack onset.
Once treatment has been initiated, time to onset of relief should occur within 30 to 120 minutes.

View source ↗